Heart failure drug vericiguat put to the test in small trial
NCT ID NCT05420012
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed phase 4 trial tested whether vericiguat, a drug already approved for heart failure, can improve blood vessel function, reduce inflammation, and enhance quality of life in 26 people with heart failure with reduced ejection fraction. Participants received either vericiguat or a placebo, and researchers measured changes in artery dilation, walking distance, and symptom scores. The study aims to identify which patients might benefit most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
vericiguat (Verquvo)
What this could lead to
If successful, vericiguat could become a new option to improve blood vessel health and quality of life for people with heart failure.
What could go wrong
This is a small, early-phase trial with only 26 participants, so results may not apply broadly. The drug may not show meaningful benefits over placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Utah Hospital
Salt Lake City, Utah, 84132, United States
-
Veterans Affairs Salt Lake City Health Care System (VAMC)
Salt Lake City, Utah, 84148, United States